FindTrial
Sign In

SEA-TGT

DRUG2 trials

Sponsors

Seagen Inc., Pfizer

Conditions

Bladder CancerCarcinoma, Non-Small-Cell LungCervical CancerClassical Hodgkin LymphomaCutaneous MelanomaDiffuse Large B-cell LymphomaGastric CarcinomaGastroesophageal Junction Carcinoma

Phase 1

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
TerminatedNCT04254107
Seagen Inc.Bladder Cancer, Cervical Cancer, Classical Hodgkin Lymphoma +9
Start: 2020-05-29End: 2023-12-01Updated: 2025-02-10
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
TerminatedNCT04585815
PfizerCarcinoma, Non-Small-Cell Lung
Start: 2020-11-10End: 2024-10-29Updated: 2026-01-09

Related Papers

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
2023-08-075 citations
Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies
Cancer Research2023-04-144 citations
Abstract 6361: A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody
Cancer Research2023-04-044 citations
Abstract 5668: Using clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)
Cancer Research2023-04-042 citations
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)
Regular and Young Investigator Award Abstracts2021-11-011 citations
456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress
Regular and Young Investigator Award Abstracts2021-11-011 citations
SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).
Journal of Clinical Oncology2021-05-209 citations
250 SEA-TGT is a nonfucosylated antibody with distinct and amplified effector function activity that leverages the dependencies of anti-TIGIT anti-tumor activity upon Fc? R engagement
Regular and Young Investigator Award Abstracts2020-11-013 citations